ClinicalTrials.Veeva

Menu

To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Diabetic Neuropathy, Painful

Treatments

Drug: Pregabalin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00150423
1008-165

Details and patient eligibility

About

To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must have met the inclusion criteria for the preceding double-blind BID study in painful diabetic peripheral neuropathy
  • Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion criteria

  • Patients may not participate if they experienced a serious adverse event during the preceding double-blind BID study which was determined to be related to the study medication.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems